AzTrials
AzTrials

Carotid Artery StenosisROADSAVERNCT03504228

Prospective Single Arm CAS - ROADSAVER Study

An observational study of Carotid Artery Stenosis, run by Terumo Europe N.V. at 57 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Carotid Artery Stenosis
What is being tested?
Roadsaver
Type of treatment
Medical device
How many people
1,967 participants
Where
57 sitesin 13 countries
Study dates
23 Jan 2018to 20 Jun 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients included in this study will be comprised of male and female patients derived from general interventional radiology or angiology populations.

Who may be able to join

  • The patient has a non-occlusive and non-thrombotic carotid artery stenosis and is eligible to be treated with Roadsaver Carotid Stent as per the Instructions for Use (IFU)
  • The patient is at least 18 years of age
  • The patient has a life expectancy of at least 12 months from the date of the index procedure
  • The patient is able and willing to provide a signed IRB-/EC-approved informed consent form prior to participation

Who cannot join

  • Any condition that makes patient unsuitable for percutaneous transluminal angioplasty (PTA), including intolerance or allergy to any material used and accompanying therapy

Trial locations and contacts

57 sites in 13 countries.

57 sites in 13 countries

Germany13 sites
  • Ihre-Radiologen.de

    Berlin

  • Sankt-Gertrauden Krankenhaus

    Berlin

  • Fürst-Stirum-Klinik

    Bruchsal

  • Diakonissenkrankenhaus Flensburg Ev.-Luth. Diakonissenanstalt zu Flensburg

    Flensburg

  • Cardioangiological Center Bethanien

    Frankfurt am Main

  • SRK Karlsbad

    Karlsbad

  • Theresienkrankenhaus Mannheim

    Mannheim

  • St. Franziskus-Hospital Münster

    Münster

  • Pius Hospital Oldenburg

    Oldenburg

  • Klinikum Passau

    Passau

  • Elblandklinikum Radebeul

    Radebeul

  • SRH Zentralklinikum Suhl

    Suhl

  • Universitäts und Rehabilitationskliniken Ulm

    Ulm

Other trials in Germany

Spain12 sites
  • Hospital Universitario A Coruña

    A Coruña

  • Hospital Clinico de Barcelona

    Barcelona

  • Hospital Vall D'Hebron

    Barcelona

  • Hospital Universitario Girona Josep Trueta

    Girona

  • Complejo Hospitalario De Jaen

    Jaén

  • Hospital 12 de Octubre

    Madrid

  • Hospital Quironsalud Marbella

    Marbella

  • Hospital Universitario Son Espases

    Palma de Mallorca

  • Hospital Universitario Donostia

    San Sebastián

  • Hospital universitario de Canarias

    Santa Cruz de Tenerife

  • Hospital Virgen de La Salud de Toledo

    Toledo

  • Hospital Universitario Clínico de Valladolid

    Valladolid

Other trials in Spain

Hungary7 sites
  • Markusovszky Teaching Hospital

    Budapest

  • Semmelweis University Heart and Vascular Center

    Budapest

  • Moritz Kaposi Teaching Hospital

    Kaposvár

  • Bacs-Kiskun County Hospital

    Kecskemét

  • University of Pécs

    Pécs

  • Szeged University Hospital

    Szeged

  • Szent György Fejér County - University Teaching Hospital

    Székesfehérvár

Other trials in Hungary

Belgium5 sites
  • OLV Ziekenhuis

    Aalst

  • Imelda Ziekenhuis

    Bonheiden

  • AZ Sint-Blasius

    Dendermonde

  • AZ Groeninge

    Kortrijk

  • UZ Leuven

    Leuven

Other trials in Belgium

France4 sites
  • GCS Centre de Cardiologie du Pays Basque

    Bayonne

  • Groupe Hospitalier Mutualiste de Grenoble

    Grenoble

  • Hopital de la Timone 2

    Marseille

  • Polyclinique Louis Pasteur Essey Les Nancy

    Nancy

Other trials in France

Poland3 sites
  • Szpital Uniwersytecki nr.2 im. Dr J. Biziela w Bydgoszczy

    Bydgoszcz

  • Krakowski Szpital Specjalistyczny im. Jana Pawła II

    Krakow

  • Szpital Uniwersytecki w Krakowie

    Krakow

Other trials in Poland

Serbia3 sites
  • Clinical Center of Serbia

    Belgrade

  • ICVD Dedinje

    Belgrade

  • Clinical Center of Vojvodina

    Novi Sad

Other trials in Serbia

Czechia2 sites
  • University Hospital Ostrava

    Ostrava

  • Central Military Hospital Prague

    Prague

Other trials in Czechia

Netherlands2 sites
  • UMC Groningen

    Groningen

  • Sint-Antonius Ziekenhuis

    Nieuwegein

Other trials in Netherlands

North Macedonia2 sites
  • City General Hospital 8th September Skopje

    Skopje

  • University Clinic of Cardiology

    Skopje

Other trials in North Macedonia

Slovakia2 sites
  • Cinre S.R.O.

    Bratislava

  • Kardiocentrum Nitra

    Nitra

Other trials in Slovakia

Latvia1 site
  • Paul Stradins Clinical University Hospital

    Riga

Other trials in Latvia

Portugal1 site
  • Centro Hospitalar Vilanova Gaia/Espinho

    Vila Nova de Gaia

Other trials in Portugal

About this study

Official title: Prospective, Single-arm, Multi-center, Observational Study to Further Confirm Safety and Efficacy of the Dual-layer Micromesh Roadsaver Stent for the Treatment of Carotid Artery Stenosis in Patients Eligible for Elective Stenting Procedure

Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Follow-ups are scheduled at discharge, 30 days, and 1 year, as per local practice. Each patient will have follow-up contacts via hospital visit and/or telephone.

Read the detailed description
  1. Baseline Assessments The patient will be assessed in accordance with the hospital standard of care for patients treated with carotid artery stenting procedure, which in general includes:
  • Informed consent for data collection
  • Demographics
  • Medical History
  • Medication record
  • Physical examination
  • Carotid Duplex Ultrasound
  • Neurological Assessment
  • Diffusion weighted Magnetic Resonance Imaging (DW-MRI)
  • Procedural angiography Baseline assessments will be performed prior to the index procedure and documented in the patient medical record. Baseline assessments considered standard of care completed prior to obtaining informed consent do not need to be repeated unless the investigator feels it is medically necessary. Neurological Assessment Baseline neurological assessment is recommended in this study and will be conducted by a physician, nurse, or other allied health professional, independent of the treating physician prior to the procedure. This assessment will include the neurological signs, symptoms, and the NIH Stroke Scale. For some pre-specified subgroups, imaging studies (Carotid Duplex Ultrasound and/or Diffusion Weighted Magnetic Resonance Imaging: DW-MRI) will be performed prior to the procedure.
  1. Patient Enrollment Point A patient is considered enrolled in the study if there is full compliance with the study and RoadSaver IFU eligibility criteria, and only after successful guidewire passage through the study target lesion.
  2. Medications Patients enrolled in this study will be pre-medicated according to the hospital routine practice.
  3. Procedure The procedure will be performed according to the physician's standard of care. During the procedure, patients should receive appropriate anticoagulation and other therapy according to standard hospital practice. The use of any medication for the treatment of vessel spasm, patient agitation or discomfort, hypotension, arrhythmias, and hemodynamic changes during the procedure is at the discretion of the investigator. Standard procedures should be followed based on the Instructions for Use for the Roadsaver™ device of Terumo. If pre- and/or post-dilatation is performed, or any other device (e.g. embolic protection devices, etc.) is used at the investigator's discretion. 4.1. Treatment Failures If a Roadsaver™ Carotid Stent is not implanted due to technical reasons, another CE-marked Carotid Stent may be used to complete the procedure. Patients who do not have a successful Roadsaver™ Carotid Stent implanted during the index procedure will be considered as technical failures. Patients with technical failure will be followed only until discharge at which time they will have completed the study. All patients who receive a Roadsaver™ Carotid Stent upon enrollment in the ROADSAVER study will be included in the analysis of clinical outcomes by the end of the study. Patients with technical failures will be analyzed separately only for procedural success and for in-hospital adverse events. 4.2. Device Deficiency and Device Malfunction A device deficiency is defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety, or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. A device malfunction is defined as failure of the medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use or the Clinical Investigation Plan. In case of device deficiency or malfunction, the device deficiency form in the eCRF should be completed and the investigator is asked to make every possible effort to return the device to Terumo Europe accompanied if possible with the packaging containing the device identification (lot number). Another Roadsaver™ Carotid Stent or another stent as per operators' discretion will be used in order to complete the treatment of the patient.
  4. Post-procedure Post-procedural evaluation should be done according to the routine hospital practice prior to discharge, which in general includes:
  • Post Angiography immediately after the index procedure
  • Physical examination before discharge
  • MAE defined as the cumulative incidence of any periprocedural death or stroke
  • Adverse events including: any revascularization, major vascular and bleeding complications, other
  • Medication
  • Neurological assessment when performed
  • Diffusion-weighted magnetic resonance imaging (DW-MRI) when performed Information on the post-procedural evaluation and any interventional treatment that occurred since the procedure should be collected.
  1. Follow-Up Evaluations Patients will be followed according to routine hospital practice usually performed at 30-day and at 12-month assessment through hospital visit or through telephone contact. Investigators and research coordinators will keep notes of all telephone contacts with the patients in the patient hospital file as source documents.

Hospital Visit at 1 month (30 ± 7 days) and 12 months (365 ± 30 days) Patients' clinical status should be reported if hospital visits are done at 30 days and 12 months.

These follow-up assessments should be done according to the routine hospital practice, which in general includes:

  • Physical examination
  • Adverse events including: any stroke, any Revascularization, major vascular and bleeding complications, other
  • Medication
  • Neurological assessment
  • Carotid duplex ultrasound
  • Diffusion-weighted magnetic resonance imaging (DW-MRI)

All relevant information obtained during follow-up including imaging should be reported. Data to be collected at follow-ups would include:

Telephone Contact at 12 months (365 ±30 days)

  • Adverse Events including: any death (stroke related/other), any stroke, any revascularization, major vascular and bleeding complications, other
  • Medication In case of death, stroke, TLR, and TVR all efforts should be made to provide sufficient baseline and event documentation.

Unscheduled Follow-Up

The assessment at unscheduled visits should be performed according to safety reporting requirements, which in general includes:

  • Physical examination
  • Adverse events including: any stroke, any revascularization, major vascular and bleeding complications, other
  • Medication
  • Neurological assessment
  • Carotid duplex ultrasound
  • Diffusion-weighted magnetic resonance imaging (DW-MRI)

A patient who returns to the investigational site between pre-determined visits with an event related to the index procedure should be treated according to the physician's standard of care. Reportable events occurring during this period should be collected.

Being tested
Roadsaver
Medical subject headings
Carotid Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RoadsaverDevice

    Dual layer micromesh Roadsaver carotid stent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The rate of Major Adverse Events (MAE)

    Defined as the cumulative incidence of any death or stroke up to 30 days after the index procedure.

    Measured: Up to 30 days

Secondary outcomes (11)
  1. Technical Success

    Defined as a successful access and deployment of the device with recanalization, determined by <30% residual stenosis by angiography during the index procedure.

    Measured: Peri-procedural

  2. Procedural success

    Defined as technical success with no device-/procedure-related death, stroke or any other serious adverse events.

    Measured: Peri-procedural

  3. Device malfunction

    Defined as the failure of a device after its introduction into the patient (i.e. failure to perform in accordance with its intended purpose when used as per the Instructions For Use or the Clinical Investigation Plan).

    Measured: Peri-procedural

  4. Any death

    Adjudicated by an independent Clinical Events Committee.

    Measured: Up to 30 days

  5. Stroke-related death

    Defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a stroke.

    Measured: Up to 30 days

  6. Any stroke

    Defined as an acute neurologic event with focal symptoms and signs, lasting for 24 hours or more (Adjudicated by an independent Clinical Events Committee).

    Measured: Up to 30 days

  7. Major stroke

    Defined as a new neurological event that persists for > 24 hours and results in a > 4 point increase in the NIHSS score relative to baseline or any subsequent lower score (Adjudicated by an independent Clinical Events Committee).

    Measured: Up to 30 days

  8. Minor stroke

    Defined as a new neurological event that resolves completely within 7 days or increases the NIHSS by ≤4 points (Adjudicated by an independent Clinical Events Committee).

    Measured: Up to 30 days

  9. Transient ischemic attack

    TIA

    Measured: Up to 30 days

  10. Target lesion revascularization (TLR)

    Defined as any revascularization procedure of the original treatment site, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase the luminal diameter inside or within 5 mm of the previously treated lesion (Adjudicated by an independent clinical events committee).

    Measured: Up to 30 days

  11. Major vascular and bleeding complications:

    1. Major hematoma, i.e. one requiring transfusion, surgical evacuation, or delay in discharge,
    2. Pseudo aneurysm or arteriovenous fistula or retroperitoneal bleeding,
    3. Peripheral ischemia/nerve injury caused by the proximal access site,
    4. Vascular surgical repair to correct a local vascular access site complication and bleeding.

    Measured: Up to 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2018
  2. Study start23 Jan 2018
  3. Primary completion18 Feb 2021
  4. Study completion20 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
1,967 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03504228
Sponsor's protocol ID
T130E2
Acronym
ROADSAVER
Status last verified
Jan 2023
First submitted
15 Mar 2018
Last updated
21 Mar 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Muller-Hulsbeck S, Vajda Z, Odrowaz-Pieniazek P, Ruzsa Z, Beelen R, Gjoreski A, Deloose K, Castro S, Faurie B, Tomasello Weitz A, Schwindt A, Latacz P, Orgaz Perez-Grueso A, Cvetic V, Langhoff R, Kedev S; all ROADSAVER study investigators. Contemporary carotid artery stenting practices and peri-procedural outcomes in different European countries: ROADSAVER study multicentric insights. CVIR Endovasc. 2025 Apr 12;8(1):29. doi: 10.1186/s42155-025-00528-z.

    PubMed 40220262
  • Kedev S, Muller-Hulsbeck S, Langhoff R. "Real-World Study of a Dual-Layer Micromesh Stent in Elective Treatment of Symptomatic and Asymptomatic Carotid Artery Stenosis (ROADSAVER)". Cardiovasc Intervent Radiol. 2022 Mar;45(3):277-282. doi: 10.1007/s00270-021-03051-5. Epub 2022 Jan 18.

    PubMed 35043241

Questions about this trial

What is this clinical trial studying?

An observational study of Carotid Artery Stenosis, run by Terumo Europe N.V. at 57 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 57 sites in Germany, Spain, Hungary, Belgium, France and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The rate of Major Adverse Events (MAE) (time frame: Up to 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03504228, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in